COMMUNIQUÉ DE PRESSE
News
-
-
-
-
COMMUNIQUÉ DE PRESSE
Formycon invites to conference call on the results of the financial year 2024 and announces participation in international investor conferences in the 2nd quarter of 2025
Formycon announces conference call for fiscal year 2024 results and participation in investor conferences in Q2 2025 -
-
-
COMMUNIQUÉ DE PRESSE
FYB202/Otulfi® (ustekinumab-aauz), a biosimilar to Stelara®, launched in the United States and the European Union
FYB202/Otulfi® (ustekinumab-aauz), a biosimilar to Stelara®, officially launched in the United States and European Union, offering comparable efficacy and safety. Formycon AG and Fresenius ensure successful market access -
-
-
COMMUNIQUÉ DE PRESSE
Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE®
Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE®. Approval for treating retinal diseases granted by UK's MHRA
